EA200500576A1 - ИНДУЦИБЕЛЬНЫЙ ЛИГАНД ИНТЕГРИНА α1β1 И ПРИМЕНЕНИЯ - Google Patents
ИНДУЦИБЕЛЬНЫЙ ЛИГАНД ИНТЕГРИНА α1β1 И ПРИМЕНЕНИЯInfo
- Publication number
- EA200500576A1 EA200500576A1 EA200500576A EA200500576A EA200500576A1 EA 200500576 A1 EA200500576 A1 EA 200500576A1 EA 200500576 A EA200500576 A EA 200500576A EA 200500576 A EA200500576 A EA 200500576A EA 200500576 A1 EA200500576 A1 EA 200500576A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- integrine
- applications
- induced ligand
- ligand
- induced
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Настоящее изобретение направлено на идентификацию и применение агентов, в частности пептидов и моноклональных антител, которые нарушают взаимодействие коллагена XIII и интегрина α1β1.Отчет о международном поиске был опубликован 2005.04.28.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42329702P | 2002-11-01 | 2002-11-01 | |
PCT/US2003/034818 WO2004041846A2 (en) | 2002-11-01 | 2003-10-31 | INDUCIBLE LIGAND FOR α1β1 INTEGRIN AND USES |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200500576A1 true EA200500576A1 (ru) | 2006-02-24 |
Family
ID=32312635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200500576A EA200500576A1 (ru) | 2002-11-01 | 2003-10-31 | ИНДУЦИБЕЛЬНЫЙ ЛИГАНД ИНТЕГРИНА α1β1 И ПРИМЕНЕНИЯ |
Country Status (14)
Country | Link |
---|---|
US (2) | US7348002B2 (ru) |
EP (1) | EP1562632B1 (ru) |
JP (1) | JP2006516024A (ru) |
KR (1) | KR20050084921A (ru) |
CN (1) | CN1826137A (ru) |
AU (1) | AU2003287435A1 (ru) |
BR (1) | BR0315054A (ru) |
CA (1) | CA2504125A1 (ru) |
EA (1) | EA200500576A1 (ru) |
IS (1) | IS7832A (ru) |
MX (1) | MXPA05004563A (ru) |
NO (1) | NO20052495L (ru) |
PL (1) | PL376714A1 (ru) |
WO (1) | WO2004041846A2 (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA05004563A (es) * | 2002-11-01 | 2005-07-26 | Boys Town Nat Res Hospital | Ligando inducible para la integrina alfa1beta1 y usos. |
ES2304069B1 (es) * | 2003-08-22 | 2009-08-12 | Proyecto De Biomedicina Cima, S.L. | Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1). |
JP2008512463A (ja) * | 2004-09-08 | 2008-04-24 | ボーイズ タウン ナショナル リサーチ ホスピタル | マトリックスメタロプロテイナーゼ−12に関連する糸球体基底膜疾患の治療 |
US7718765B2 (en) * | 2005-11-16 | 2010-05-18 | The University Of Tennessee Research Foundation | Methods of treating fibrosing diseases by induction of immune tolerance |
PL2200622T5 (pl) * | 2007-09-19 | 2016-08-31 | Pluristem Ltd | Adherentne komórki z tkanki tłuszczowej i łożyska i ich zastosowanie w terapii |
US9719981B2 (en) | 2012-08-17 | 2017-08-01 | Father Flanagan's Boys' Home | RAC1 inhibitors for the treatment of alport glomerular disease |
CN114887034B (zh) * | 2022-07-14 | 2022-10-28 | 中山莱博瑞辰生物医药有限公司 | LLP2A-Ale在制备用于治疗和/或预防外周血淋巴细胞减少症的药物中的用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5391481A (en) * | 1990-08-31 | 1995-02-21 | The Trustees Of Columbia University | Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof |
US5462990A (en) * | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
JPH08151396A (ja) * | 1994-11-28 | 1996-06-11 | Teijin Ltd | Hla結合性オリゴペプチド及びそれを含有する免疫調節剤 |
US6492325B1 (en) * | 1998-05-22 | 2002-12-10 | Boys Town National Research Hospital | Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease |
NZ508317A (en) * | 1998-05-22 | 2004-01-30 | Boys Town Nat Res Hospital | Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease |
ES2529706T3 (es) * | 1999-06-01 | 2015-02-24 | Biogen Idec Ma Inc. | Un anticuerpo monoclonal bloqueante contra el dominio alfa1-I de VLA-1, y su uso para el tratamiento de trastornos inflamatorios |
GB2356401A (en) * | 1999-11-19 | 2001-05-23 | Proteom Ltd | Method for manipulating protein or DNA sequence data |
MXPA05004563A (es) * | 2002-11-01 | 2005-07-26 | Boys Town Nat Res Hospital | Ligando inducible para la integrina alfa1beta1 y usos. |
-
2003
- 2003-10-31 MX MXPA05004563A patent/MXPA05004563A/es not_active Application Discontinuation
- 2003-10-31 EP EP03781670A patent/EP1562632B1/en not_active Expired - Lifetime
- 2003-10-31 WO PCT/US2003/034818 patent/WO2004041846A2/en active Application Filing
- 2003-10-31 BR BR0315054-2A patent/BR0315054A/pt not_active IP Right Cessation
- 2003-10-31 JP JP2004550398A patent/JP2006516024A/ja not_active Withdrawn
- 2003-10-31 US US10/698,121 patent/US7348002B2/en not_active Expired - Fee Related
- 2003-10-31 AU AU2003287435A patent/AU2003287435A1/en not_active Withdrawn
- 2003-10-31 CN CNA200380108181XA patent/CN1826137A/zh active Pending
- 2003-10-31 KR KR1020057007789A patent/KR20050084921A/ko not_active Application Discontinuation
- 2003-10-31 EA EA200500576A patent/EA200500576A1/ru unknown
- 2003-10-31 CA CA002504125A patent/CA2504125A1/en not_active Abandoned
- 2003-10-31 PL PL376714A patent/PL376714A1/pl unknown
-
2005
- 2005-04-29 IS IS7832A patent/IS7832A/is unknown
- 2005-05-24 NO NO20052495A patent/NO20052495L/no not_active Application Discontinuation
-
2008
- 2008-02-08 US US12/069,297 patent/US7662382B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NO20052495D0 (no) | 2005-05-24 |
EP1562632A2 (en) | 2005-08-17 |
CN1826137A (zh) | 2006-08-30 |
EP1562632A4 (en) | 2007-01-17 |
US7662382B2 (en) | 2010-02-16 |
WO2004041846A3 (en) | 2005-04-28 |
BR0315054A (pt) | 2005-08-16 |
MXPA05004563A (es) | 2005-07-26 |
EP1562632B1 (en) | 2012-12-05 |
CA2504125A1 (en) | 2004-05-21 |
AU2003287435A2 (en) | 2004-06-07 |
US20040253241A1 (en) | 2004-12-16 |
US7348002B2 (en) | 2008-03-25 |
NO20052495L (no) | 2005-07-25 |
KR20050084921A (ko) | 2005-08-29 |
PL376714A1 (pl) | 2006-01-09 |
WO2004041846A2 (en) | 2004-05-21 |
IS7832A (is) | 2005-04-29 |
US20080227121A1 (en) | 2008-09-18 |
AU2003287435A1 (en) | 2004-06-07 |
JP2006516024A (ja) | 2006-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2187954T3 (es) | Anticuerpos anti-integrina avb3 antagonistas. | |
DE69433406T2 (de) | Antikörper gegen cd40 | |
NO20031049D0 (no) | Syntetiske erytropoese-stimulerende proteiner | |
EA199801043A1 (ru) | Антитела против домена ed-в в фибронектина, их конструирование и использование | |
DE69813158T2 (de) | Assays zur Bestimmung von Proteinfragmenten in biologischen Medien | |
ATE438662T1 (de) | Verbesserte fc-fusionsproteine | |
NO20001238L (no) | Monoklonalt antistoff som induserer apoptose | |
EA200501444A1 (ru) | Экспрессирующие векторы, содержащие ie2-промотор mcmv | |
ATE489623T1 (de) | Peptide zum nachweis von ehrlichia ewingii antikörper | |
EA200500576A1 (ru) | ИНДУЦИБЕЛЬНЫЙ ЛИГАНД ИНТЕГРИНА α1β1 И ПРИМЕНЕНИЯ | |
ATE467124T1 (de) | Mit prp sp sc/sp wechselwirkende moleküle und deren verwendung | |
ATE368225T1 (de) | Verwendung von antikörpern gegen spezifische mhc- peptidkomplexe | |
ATE517926T1 (de) | Antikörper zur hemmung der aktivität von mmp-2 und mmp-9 | |
NO20000215D0 (no) | Adipocyttspesifikke proteinhomologer | |
EA200401628A1 (ru) | Ингибиторы пептидной деформилазы | |
ATE513040T1 (de) | Zinkfingerdomänenbibliotheken | |
DE602004009824D1 (de) | Analyse von massenspektraldaten in den ruhigen gebieten | |
EA200600639A1 (ru) | Пептид, происходящий из вируса гепатита с | |
EP1609804A4 (en) | CONSTRUCT CONTAINS THE DETECTION DOMAIN OF ANTIBODIES AGAINST WILLEBRAND FACTOR-SPECIFIC CLEAVING ENZYMES | |
DE602004009056D1 (de) | N-(2-phenylethyl)sulfamid-derivate als integrin-alpha4-antagonisten | |
ATE296102T1 (de) | Liganden von integrinrezeptoren | |
EA200400393A1 (ru) | Антитела против каспазы-8, их получение и применение | |
ATE305041T1 (de) | Kompositionen und verwendungen von cgi-69 | |
ATE470678T1 (de) | Emitter-bindende peptide, die eine veränderung der spektralen emissionseigenschaften des emitters bewirken | |
DK0994187T3 (da) | Renin-aktivt stof omfattende humant prorenin og antistoffer mod prorenin-profragmentet |